Head and Neck Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Head and Neck Cancer Pipeline Drugs Market Report Overview
Head and Neck Cancer symptoms include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. Treatment includes chemotherapy and radiation therapy.
The Head and Neck Cancer pipeline drugs market research report provides an analysis of the Head and Neck Cancer drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Head and Neck Cancer and features dormant and discontinued projects.
| Key Targets | Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Epidermal Growth Factor Receptor, Cells Expressing Epidermal Growth Factor Receptor, Tubulin, Human Papillomavirus Protein E7, Vascular Endothelial Growth Factor Receptor 2, Cytotoxic T Lymphocyte Protein 4, Vascular Endothelial Growth Factor Receptor 3, Human Papillomavirus Protein E6, and Mast/Stem Cell Growth Factor Receptor Kit |
| Key Mechanisms of Action | Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Epidermal Growth Factor Receptor Antagonist, Tubulin Inhibitor, Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Epidermal Growth Factor Receptor Inhibitor, and Vascular Endothelial Growth Factor Receptor 1 Inhibitor |
| Key Routes of Administration | Intravenous, Oral, Parenteral, Subcutaneous, Intravenous Drip, Intratumor, Intraperitoneal, Intravesical, Intramuscular, Intradermal, and Intralesional |
| Key Molecule Types | Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Cell Therapy, Fusion Protein, Subunit Vaccine, Oncolytic Virus, Biologic, and Recombinant Vector Vaccine |
| Key Companies | AstraZeneca Plc, Bristol-Myers Squibb Co, Incyte Corp, Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co Inc, AbbVie Inc, Bayer AG, Pfizer Inc, Advenchen Laboratories LLC, and Shanghai Henlius Biotech Inc |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Head and Neck Cancer Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Head and Neck Cancer pipeline drugs market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Epidermal Growth Factor Receptor, Cells Expressing Epidermal Growth Factor Receptor, Tubulin, Human Papillomavirus Protein E7, Vascular Endothelial Growth Factor Receptor 2, Cytotoxic T Lymphocyte Protein 4, Vascular Endothelial Growth Factor Receptor 3, Human Papillomavirus Protein E6, and Mast/Stem Cell Growth Factor Receptor Kit among others. In 2022, Programmed Cell Death Protein 1 was the dominant target in the Head and Neck Cancer pipeline drugs market.
Head and Neck Cancer Pipeline Drugs Market Analysis by Targets, 2022 (%)
Buy the full report for more insights on key targets in the Head and Neck Cancer Pipeline Drugs Market or download a free report sample
Head and Neck Cancer Pipeline Drugs Market Segmentation by Mechanisms of Action
The mechanisms of action of the Head and Neck Cancer pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Epidermal Growth Factor Receptor Antagonist, Tubulin Inhibitor, Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Epidermal Growth Factor Receptor Inhibitor, and Vascular Endothelial Growth Factor Receptor 1 Inhibitor among others. In 2022, Programmed Cell Death Protein 1 Antagonist was the dominant MoA in the Head and Neck Cancer pipeline drugs market.
Head and Neck Cancer Pipeline Drugs Market Analysis by Key Mechanisms of Action, 2022 (%)
Buy the full report for more insights on mechanisms of action in the Head and Neck Cancer Pipeline Drugs Market, download a free report sample
Head and Neck Cancer Pipeline Drugs Market Segmentation by Routes of Administration
The routes of administration in the Head and Neck Cancer pipeline drugs market are intravenous, oral, intratumor, subcutaneous, parenteral, intravenous drip, intramuscular, intradermal, intraperitoneal, intravesical, topical, and intralesional among others. In 2022, the intravenous RoA was the most preferred segment in the Head and Neck Cancer pipeline drugs market.
Head and Neck Cancer Pipeline Drugs Market Analysis by Routes of Administration, 2022 (%)
For more insights on routes of administration in the Head and Neck Cancer Pipeline Drugs Market, buy the full report or download a free report sample
Head and Neck Cancer Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Head and Neck Cancer pipeline drugs market are Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Cell Therapy, Fusion Protein, Subunit Vaccine, Oncolytic Virus, Biologic, and Recombinant Vector Vaccine among others. In 2022, the most preferred molecule type in the Head and Neck Cancer pipeline drugs market was small molecules.
Head and Neck Cancer Pipeline Drugs Market Analysis by Molecule Types, 2022 (%)
Buy the full report for more insights on molecule type in the Head and Neck Cancer Pipeline Drugs Market, download a free report sample
Leading Companies in the Head and Neck Cancer Pipeline Drugs Market
Some of the leading companies in the Head and Neck Cancer pipeline drugs market are AstraZeneca Plc, Bristol-Myers Squibb Co, Incyte Corp, Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co Inc, AbbVie Inc, Bayer AG, Pfizer Inc, Advenchen Laboratories LLC, and Shanghai Henlius Biotech Inc among others.
Head and Neck Cancer Pipeline Drugs Market Analysis by Leading Companies, 2022 (%)
For more insights on companies in the Head and Neck Cancer Pipeline Drugs Market, buy the full report or download a free report sample
Key Segments Covered in this Report
Head and Neck Cancer Pipeline Drugs Target Outlook (%, 2022)
- Programmed Cell Death Protein 1
- Programmed Cell Death 1 Ligand 1
- Epidermal Growth Factor Receptor
- Cells Expressing Epidermal Growth Factor Receptor
- Others
Head and Neck Cancer Pipeline Drugs MoA Outlook (%, 2022)
- Programmed Cell Death Protein 1 Antagonist
- Programmed Cell Death 1 Ligand 1 Inhibitor
- Epidermal Growth Factor Receptor Antagonist
- Tubulin Inhibitor
- Others
Head and Neck Cancer Pipeline Drugs RoA Outlook (%, 2022)
- Intravenous
- Oral
- Intratumor
- Subcutaneous
- Parenteral
- Others
Head and Neck Cancer Pipeline Drugs Molecule Type Outlook (%, 2022)
- Small Molecule
- Monoclonal Antibody
- Monoclonal Antibody Conjugated
- Others
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Head and Neck Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Head and Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Head and Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Head and Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Head and Neck Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Head and Neck Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Head and Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
4D Pharma Plc
4SC AG
A2 Biotherapeutics Inc
Aadi Bioscience Inc
ABBA Therapeutics AG
AbbVie Inc
Accendatech Co Ltd
Achilles Therapeutics Plc
Actuate Therapeutics Inc
Adagene Suzhou Ltd
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Advanced Accelerator Applications SA
Advaxis Inc
Advenchen Laboratories LLC
Adze Biotechnology Inc
Affimed GmbH
AGC Biologics SpA
Agenus Inc
AilseVax Ltd
Akeso Inc
Alkermes Plc
Alligator Bioscience AB
Alphageneron-Pharmaceuticals Inc
Alphamab Oncology
Alpine Immune Sciences Inc
ALX Oncology Holdings Inc
Ambrx Biopharma Inc
amcure GmbH
Amgen Inc
Aminex Therapeutics Inc
AnBogen Therapeutics
ANP Technologies Inc
Anteris Technologies Ltd
AP Biosciences Inc
Apexigen Inc
Apollomics Inc
Arch Oncology Inc
Arcus Biosciences Inc
Argenx SE
Ascenta Therapeutics Inc
Ascentage Pharma Group Inc
Ascentage Pharma Group International
Asclepiumm Taiwan Co Ltd
Asher Biotherapeutics Inc
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Athenex Inc
Atreca Inc
Aura Biosciences Inc
Aurigene Discovery Technologies Ltd
Avacta Life Sciences Ltd
Avalon GloboCare Corp
AVEO Pharmaceuticals Inc
Avesthagen Ltd
Aveta Biomics Inc
Avvinity Therapeutics Ltd
Bavarian Nordic AS
Bayer AG
BeiGene Ltd
Beijing Biostar Technologies Ltd
Beijing Corregene Biotechnology Co Ltd
Beijing Scitech-MQ Pharmaceuticals Ltd
Beijing Weiyuan Likang Biological Technology Co
Bicara Therapeutics Inc
Bicycle Therapeutics Plc
Bika Biotechnology Guanzhou Co Ltd
Bio-Synectics Inc
Bio-Thera Solutions Ltd
BioAtla Inc
BioCurity Pharmaceuticals Inc
Biohaven Pharmaceutical Holding Company Ltd
BioLineRx Ltd
Biomics Biotechnologies Co Ltd
Biomimetix JV LLC
Biomunex Pharmaceuticals
BioNTech SE
Biosion Inc
BioSyngen Pte Ltd
Biotheus Inc
Bioven Group
Bioviz Technologies Pvt Ltd
BJ Bioscience Inc
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
BP InnoMed Ltd
BrightPath Biotherapeutics Co Ltd
Bristol-Myers Squibb Co
Brooklyn ImmunoTherapeutics Inc
Byondis BV
Calico Life Sciences LLC
Calidi Biotherapeutics Inc
Calithera Biosciences Inc
CanBas Co Ltd
Cancer Therapeutics Laboratories Inc
Canget BioTekpharma LLC
Cantargia AB
CarboMimetics
Cardiff Oncology Inc
CDR-Life Inc
CEL-SCI Corp
Celcuity Inc
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Cello Therapeutics Inc
Celprogen Inc
Celularity Inc
Centrymed Pharmaceutical Inc
Centurion BioPharma Corp
Checkpoint Therapeutics Inc
Chengdu Wonho Biology Engineering Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
China Immunotech Co Ltd
Chinook Therapeutics Inc
Codiak BioSciences Inc
Coherent Biopharma
Compugen Ltd
Cortexyme Inc
Corvus Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Cue Biopharma Inc
Curevac NV
Curigin Co Ltd
Curis Inc
Cyclacel Pharmaceuticals Inc
Cyclica Inc
Cyteir Therapeutics Inc
CytImmune Sciences Inc
Cytodyn Inc
CytomX Therapeutics Inc
Cytovation AS
DAE HWA Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
DNJ Pharma Inc
Dracen Pharmaceuticals Inc
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
Duet Therapeutics Inc
Dyadic International Inc
Edison Oncology Holding Corp
eFFECTOR Therapeutics Inc
Eisai Co Ltd
Elevation Oncology Inc
Eli Lilly and Co
Elicio Therapeutics Inc
Elixiron Immunotherapeutics Inc
Elpiscience Biopharma Ltd
ENB Therapeutics LLC
Enhancedbio Inc
Enzene Biosciences Ltd
EpicentRx Inc
EpimAb Biotherapeutics Inc
EpiThany Inc
Epizyme Inc
Erasca Inc
eTheRNA Immunotherapies NV
Euclises Pharmaceuticals Inc
Faron Pharmaceuticals Oy
Fate Therapeutics Inc
Flow Pharma Inc
Fochon Pharmaceutical Ltd
Forbius
Frezent Biological Solutions Inc
Fujifilm Holdings Corp
FUJIFILM Toyama Chemical Co Ltd
Fusion Pharmaceuticals Inc
G&E Herbal Biotechnology Co., Ltd.
Galectin Therapeutics Inc
Galera Therapeutics Inc
Geneius Biotechnology Inc
Genelux Corp
Genentech USA Inc
GeneQuantum Healthcare Suzhou Co Ltd
Genexine Inc
GenFleet Therapeutics (Shanghai) Inc
GenKyoTex SA
Genmab AS
Genocea Biosciences Inc
Genome & Co
Genor BioPharma Co Ltd
GeoVax Labs Inc
Gilead Sciences Inc
GLG Pharma SA
Gliknik Inc
Glycomantra Inc
GlycoMira Therapeutics Inc
Glycostem Therapeutics BV
Glycotope GmbH
GO Therapeutics Inc
GSK plc
GT Biopharma Inc
Guangzhou Bairui Biomedical Technology Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Guangzhou Doublle Bioproduct Inc
Guangzhou Sinogen Pharmaceutical Co Ltd
Guangzhou Yinming Biomedical Technology Co Ltd
Handok Inc
Hangzhou DAC Biotech Co Ltd
Hangzhou Zenshine Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
HDT Bio Corp
Hercules Pharmaceuticals BV
Hibercell Inc
HiFiBiO Therapeutics Inc
Highlight Therapeutics SL
Hillstream BioPharma Inc
HitGen Inc
Hookipa Pharma Inc
Horizon Therapeutics Plc
HRYZ (ShenZhen) Biotech Co
Huabo Biopharm (Shanghai) Co Ltd
Hummingbird Bioscience Pte Ltd
HylaPharm
I-Mab
Ideaya Biosciences Inc
Idera Pharmaceuticals Inc
IGM Biosciences Inc
Ikena Oncology Inc
ImCheck Therapeutics SAS
Immatics NV
Immix BioPharma Inc
Immodulate Pharma AB
ImmuneOnco Biopharmaceuticals
ImmuneSensor Therapeutics Inc
ImmunityBio Inc
Immunocore Limited
Immunogenesis Inc
Immunome Inc
Immunomic Therapeutics Inc
Immutep Ltd
Immvira Co Ltd
Imugene Ltd
IMV Inc
Incyte Corp
Infinity Pharmaceuticals Inc
Inhibrx Inc
Inmune Bio Inc
InnoCare Pharma Ltd
InnoMab Pte Ltd
Innovative Cellular Therapeutics Co
Innovene
Innovent Biologics Inc
Inovio Pharmaceuticals Inc
Instil Bio Inc
ISU ABXIS Co Ltd
iTeos Therapeutics Inc
Jacobio Pharmaceuticals Group Co Ltd
Janux Therapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Vcare PharmaTech Co Ltd
Jiangxi Jemincare Group Co Ltd
Jiangxi Qingfeng Pharmaceutical Co Ltd
Jina Pharmaceuticals Inc
Johnson & Johnson
Joint Biosciences Ltd
Jounce Therapeutics Inc
Jubilant Therapeutics Inc
Karyopharm Therapeutics Inc
Kiadis Pharma NV
Kineta Inc
Komipharm International Co Ltd
Kymab Ltd
Kyowa Kirin Co Ltd
L&L Biopharma Co Ltd
L.E.A.F. Pharmaceuticals LLC
Laboratoires Pierre Fabre SA
LATITUDE Pharmaceuticals Inc
Leucid Bio Ltd
Lidds AB
LIfT BioSciences Ltd
LightOx Ltd
Linnaeus Therapeutics Inc
Lion TCR Pte Ltd
LipoSeuticals Inc
Luminus Biosciences Inc
Luye Pharma Group Ltd
Luzitin SA
Lycera Corp
LynkCell Inc
Lytix Biopharma AS
Lyvgen Biopharma Ltd
Mabion SA
Mabpharm Ltd
MacroGenics Inc
MAIA Biotechnology Inc
ManysmarT Therapeutics Inc
Mekanistic Therapeutics LLC
Memgen Inc
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Merus NV
Metaclipse Therapeutics Corp
Millennium Pharmaceuticals Inc
MiNK Therapeutics Inc
Mirati Therapeutics Inc
MiRecule Inc
MiReven Pty Ltd
Mitsubishi Tanabe Pharma Corp
Moderna Inc
Modra Pharmaceuticals BV
Molecular Partners AG
Molecular Targeting Technologies Inc
Molecular Templates Inc
Moleculin Biotech Inc
Morphogenesis Inc
Multitude therapeutics Inc
MultiVir Inc
Nanjing Aimeifei Biomedical Technology Co Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
NanoCarrier Co Ltd
NantBioScience Inc
Natco Pharma Ltd
Nektar Therapeutics
Neonc Technologies Inc
NeoTX Therapeutics Ltd
Neumedicines Inc
NexImmune Inc
NextCure Inc
NGM Biopharmaceuticals Inc
NKGen Biotech Inc
Novartis AG
Noxopharm Ltd
Nubiyota LLC
Nurix Therapeutics Inc
Nuvectis Pharma Inc
Nykode Therapeutics ASA
Obsidian Therapeutics Inc
Ocellaris Pharma Inc
OncoResponse Inc
Oncorus Inc
OncoSec Medical Inc
Oncotelic Therapeutics Inc
Oncovir Inc
OncXerna Therapeutics Inc
Ono Pharmaceutical Co Ltd
Onxeo SA
Orgenesis Inc
Ovensa Inc
Oxford Vacmedix UK Ltd
Pact Pharma Inc
Palleon Pharmaceuticals Inc
Papivax LLC
PCI Biotech Holding ASA
PDS Biotechnology Corp
Pfizer Inc
Pharma Mar SA
Philogen SpA
Phio Pharmaceuticals Corp
Pionyr Immunotherapeutics Inc
PlantForm Corp
Plexxikon Inc
Plus Therapeutics Inc
Poseida Therapeutics Inc
Potenza Therapeutics Inc
Precigen Inc
Precision Biologics Inc
Prelude Therapeutics Inc
PRISM Pharma Co Ltd
Privo Technologies Inc
Promontory Therapeutics Inc
Protheragen Inc
Provectus Biopharmaceuticals Inc
PsiOxus Therapeutics Ltd
Psivac Ltd
Puma Biotechnology Inc
Purple Biotech Ltd
Qilu Pharmaceutical Co Ltd
Qilu Puget Sound Biotherapeutics Corp
Qrono Inc
Quadriga BioSciences Inc
Qwixel Therapeutics LLC
RaQualia Pharma Inc
Refuge Biotechnologies Inc
Regeneron Pharmaceuticals Inc
Relay Therapeutics Inc
RemeGen Co Ltd
Repare Therapeutics Inc
Repertoire Immune Medicines Inc
Replimune Ltd
Reven Holdings Inc
Ribon Therapeutics Inc
RS Research
Rubius Therapeutics Inc
Sanofi
Sareum Holdings Plc
Sathgen Biotech
Scancell Holdings Plc
Scholar Rock Inc
Seagen Inc
Secura Bio Inc
SEEKYO Therapeutics
Sensei Biotherapeutics Inc
Seven and Eight Biopharmaceuticals Corp
Shanghai Affinity Biomedical Technology Co Ltd
Shanghai De Novo Pharmatech Co Ltd
Shanghai Escugen Biotechnology Co Ltd
Shanghai Gencells Therapeutics Co Ltd
Shanghai GeneChem Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Institute of Biological Products Co Ltd
Shanghai Jing Ze Biotechnology Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Miracogen Inc
Shanghai Novamab Biopharmaceuticals Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shanghai Yuansong Biotechnology Co Ltd
Shattuck Labs Inc
Shenghe (China) Biopharmaceutical Co Ltd
Shionogi & Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Theravectys SA
TILT Biotherapeutics Ltd
Tizona Therapeutics Inc
Tmunity Therapeutics Inc
TOLREMO Therapeutics AG
TOT Biopharm Co Ltd
Touchlight Genetics Ltd
Transcenta Holding Ltd
Transgene SA
Treadwell Therapeutics Inc
TScan Therapeutics Inc
Tuhura Biopharma Inc
Turning Point Therapeutics Inc
Turnstone Biologics Inc
Tvardi Therapeutics Inc
Tyme Inc
UbiVac LLC
UCB SA
Ultimovacs AS
United Immunity Co Ltd
Vaccinex Inc
VasGene Therapeutics Inc
Vault Pharma Inc
Vaximm AG
VCN Biosciences SL
Vectorite Biomedical Inc
Venus Remedies Ltd
Versameb AG
Viracta Therapeutics Inc
Virion Therapeutics LLC
Virocure Inc
VM Discovery Inc
Table of Contents
Frequently asked questions
-
What are the targets of the Head and Neck Cancer pipeline drugs market?
Some of the targets of the Head and Neck Cancer pipeline drugs market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Epidermal Growth Factor Receptor, Cells Expressing Epidermal Growth Factor Receptor, Tubulin, Human Papillomavirus Protein E7, Vascular Endothelial Growth Factor Receptor 2, Cytotoxic T Lymphocyte Protein 4, Vascular Endothelial Growth Factor Receptor 3, Human Papillomavirus Protein E6, and Mast/Stem Cell Growth Factor Receptor Kit among others.
-
What are the mechanisms of action of the Head and Neck Cancer pipeline drugs market?
The key mechanism of action of the Head and Neck Cancer pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Epidermal Growth Factor Receptor Antagonist, Tubulin Inhibitor, Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Epidermal Growth Factor Receptor Inhibitor, and Vascular Endothelial Growth Factor Receptor 1 Inhibitor among others.
-
What are the routes of administration in the Head and Neck Cancer pipeline drugs market?
The routes of administration in the Head and Neck Cancer pipeline drugs market are intravenous, oral, parenteral, subcutaneous, intravenous drip, intratumor, intraperitoneal, intravesical, intramuscular, intradermal, and intralesional among others.
-
What are the molecule types in the Head and Neck Cancer pipeline drugs market?
The molecule types in the Head and Neck Cancer pipeline drugs market are Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Cell Therapy, Fusion Protein, Subunit Vaccine, Oncolytic Virus, Biologic, and Recombinant Vector Vaccine among others.
-
Which are the leading companies in the Head and Neck Cancer pipeline drugs market?
Some of the leading companies in the Head and Neck Cancer pipeline drugs market are AstraZeneca Plc, Bristol-Myers Squibb Co, Incyte Corp, Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co Inc, AbbVie Inc, Bayer AG, Pfizer Inc, Advenchen Laboratories LLC, and Shanghai Henlius Biotech Inc among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Head and Neck Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Oncology reports